This and other evidence, including the findings of increased ANRIL in prostate cancer, leukemia, glioma, and breast cancer suggest ANRIL, may promote tumorigenesis (19, 23–26). This evidence concerns the gene CDKN2B-AS1 and central nervous system cancer.